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Abstract
The development of molecular diagnostic tools to achieve individualized medicine
requires identifying predictive biomarkers associated with subgroups of individuals
who might receive beneficial or harmful effects from different available treatments.
However, due to the large number of candidate biomarkers in the large-scale genetic
and molecular studies, and complex relationships among clinical outcome, biomarkers
and treatments, the ordinary statistical tests for the interactions between treatments
and covariates have difficulties from their limited statistical powers. In this paper, we
propose an efficient method for detecting predictive biomarkers. We employ weighted
loss functions of Chen et al. (2017) to directly estimate individual treatment scores
and propose synthetic posterior inference for effect sizes of biomarkers. We develop
an empirical Bayes approach, namely, we estimate unknown hyperparameters in the
prior distribution based on data. We then provide the efficient ranking and selection
method of the candidate biomarkers based on this framework with adequate control
of false discovery rate. The proposed model is demonstrated in simulation studies and
an application to a breast cancer clinical study in which the proposed method was
shown to detect the much larger numbers of significant biomarkers than the current
standard methods.
Key words: Empirical Bayes; False discovery rate; Optimal discovering procedure;
Propensity score
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1 Introduction
Due to the advances of disease biology, it has been revealed that there is substantial
molecular heterogeneity among individual patients in many diseases. This implies
that the benefits and harms of many treatments might also be heterogeneous, and
accurate molecular diagnostic methods could maximize the treatment benefits for
individual patients (Gabriel and Normand, 2012). To develop the molecular diag-
nostic tools, a key task is the identification of predictive biomarkers associated with
subgroups of individuals who might receive beneficial or harmful effects from differ-
ent available treatments (Matsui et al., 2015; Lipkovich et al., 2017). It is typically
explained by interactions between the treatment and candidate biomarkers, but the
conventional interaction tests have substantial difficulties for these analyses because
of their serious limitations of statistical powers (Matsui et al., 2018).
On the other hand, efficient estimating methods of individual treatment effects
(ITE) have been also developed for large-scale genetic and molecular studies. Specifi-
cally, there is a growing number of literatures regarding the efficient estimation of ITE
(e.g. Kehl and Ulm, 2006; Tian et al., 2014; Chen et al., 2017; Lu et al., 2018; Wager
and Athey, 2018; Zhang et al., 2017) among many others. Although these methods
can effectively estimate ITE, the estimated model is typically too complicated, and
it would be difficult to understand which biomarkers are actually associate with ITE.
Besides, the regularization methods often provide us not only the estimates of model
parameters but also selection results of biomarkers included in the estimated model
(Lu et al., 2013; Zhang and Zhang, 2018), but the regularization method do not neces-
sarily guarantee the control of the degree of false discoveries, i.e., false discovery rate
(Benjamini and Hochberg, 1995). Since the primary purpose of large-scale genetic
and molecular studies is screening relevant candidate markers, the prioritization and
assessment of the accuracy of selections are relevant tasks.
In this article, we propose an efficient method for screening predictive biomarkers
associated with ITE under control of FDR. We employ the weighted loss function
proposed by Chen et al. (2017) designed to directly estimate ITE score without ex-
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plicitly specifying the main effect, and construct synthetic likelihood for effect sizes
of candidate biomarkers. The synthetic likelihood is then combined with a latent
semiparametric distribution of true effect sizes, which enables us derive the synthetic
posterior distribution for effect sizes. The underlying semiparametric distribution of
effect sizes can be estimated by the EM algorithm (Dempster et al., 1977), and we
propose the optimal discovery procedure (ODP) to detect predictive biomarkers with
adequate control of FDR. Through simulation studies, we numerically show that the
proposed method can detect much more true predictive biomarkers than standard
methods. Moreover, we apply the proposed method to an observational study of
breast cancer, and we found that the proposed methods were able to detect a large
number of predictive biomarkers whereas the standard methods detected less than 2
even when FDR is allowed to be 20%. This paper is organized as follows. In Section
2, we describe the proposed method and demonstrate the optimal discovery proce-
dure. In Section 3, we conducted simulation studies to confirm the effectiveness of
the proposed method compared with conventional testing approaches. We then apply
the proposed method to a dataset of a breast cancer study in Section 4. Finally, we
give some discussions in Section 5.
2 Proposed Method
2.1 Notations and assumptions
We adopt the notation based on the potential outcome framework in causal inference
(Rubin, 2005). Let T ∈ {−1, 1} be the treatment indicator with T = 1 indicating
a patient being treated and T = −1 indicating the opposite. Let Y (T ) denote the
potential outcome indicating the response of a patient (e.g., survival time, binary
disease status) if the patient receives treatment T . In practice, only one of the
potential outcomes Y (1) and Y (−1) can be observed for each patient, that is, Y =
I(T = 1)Y (1) + I(T = −1)Y (−1), where I(·) is the indicator function. We employ
strongly ignorable assumption (Rosenbaum and Rubin, 1983; Rubin, 2005), that is, T
is independent of (Y (1), Y (−1)) given the p-dimensional covariates X = (X1, . . . , Xp)t
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of potential predictive biomarkers of the treatment (e.g., genotypes, gene expressions).
For the treatment assignment, we assume that probability of treatment assignment
is a function of X, that is, P (T = 1|X) = pi(X), where pi(X) is known as propensity
score, and pi(X) = 1/2 under randomized clinical trial or pi(X) needs to be estimated
(e.g. via regression modeling) in observational studies. We first assume that pi(X) is
known, and provide discussions on estimating pi(X) in Section 4. The observed data
{(Yi, Xi, Ti), i = 1, . . . , n} consists of n independent identically distributed copies of
(Y, T,X).
2.2 Weighted loss function and synthetic posterior
Our goal is to detect biomarkers among X that are associated with individual treat-
ment effect (ITE) denoted by ∆(X), e.g. ∆(X) = E[Y |X,T = 1]− E[Y |X,T = −1].
Traditional approaches for estimating ∆(X) use parametric models including main
effect (function only of X) and interaction effect (function of both X and T ), thereby
the estimation of main effect (nuisance part) may lead to inefficient estimation of the
interaction effect. To avoid the problem, we here employ the weighted loss function
(Chen et al., 2017) given by
Ln(f) =
n∑
i=1
M{Yi, Tif(Xi)}
Tipi(Xi) + (1− Ti)/2 , (1)
where pi(Xi) = P (Ti = 1|Xi) is the propensity score, and M(·, ·) is a loss function. As
noted in Chen et al. (2017), there is a one-to-one correspondence between the choice
of M(u, v) and measure of treatment effect. For example, under M(u, v) = (u− v)2,
the minimizer of the true risk E[Ln(f)] is {E[Yi|Xi, Ti = 1] − E[Yi|Xi, Ti = −1]}/2,
which is difference of expectations between treatment and opposite groups.
Now we consider a linear regression model for the kth biomarker: f(X;αk, βk) =
αk +βkX, where αk is the biomarker-specific intercept and βk is the effect size of the
kth biomarker. Then, the weighted loss function (1) is reduced to
n∑
i=1
M(Yi, Tiαk + TiXikβk)
Tipi(Xi) + (1− Ti)/2 . (2)
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To define synthetic posterior distribution of effect sizes βk’s, we define synthetic like-
lihood based on the loss function (2) given by
Lk(αk, βk) = exp
[
−1
a
n∑
i=1
M(Yi, Tiαk + TiXikβk)
Tipi(Xi) + (1− Ti)/2
]
, (3)
where a is a scaling constant such that a = n−1
∑n
i=1{Tipi(Xi) + (1 − Ti)/2}−1,
and the maximizer of Lk is the same as the minimizer of (2). Note that wi =
a−1{Tipi(Xi) + (1− Ti)/2}−1 can be interpreted as the weight for the ith observation
such that
∑n
i=1wi = n. From (3), βk can be interpreted as interaction effect of Ti
and Xik, so that βk = 0 means that the kth biomarker is irrelevant to ITE; otherwise,
the kth biomarker is a predictive biomarker. Hence, we consider statistical testing
whether βk is zero or not for each k. To this end, we first note that αk is a nuisance
parameter in (2). For constructing (profile) synthetic likelihood of βk from (2), we
consider the following two methods:
1. (Plug-in method). We first compute the point estimator α̂k of αk obtained by
maximizing the synthetic likelihood function (2), and replace αk in (2) with α̂k.
2. (Normal-approximation method). We compute the mode β̂k and the inverse
value of Hessian at the mode, sk, of the synthetic likelihood function (2) with
respect to βk, and define the synthetic likelihood function of βk as φ(β̂k;βk, sk).
The synthetic likelihood of βk will be denoted by PLk(βk). Since information from
n individuals is summarized in β̂k and sk, the normal approximation method have
computational advantage compared to the plug-in method which needs to compute
summation over n individuals. However, the normal approximation might be poor
when n is not large, which may lead to less power than the plug-in method.
We consider the multiple hypothesis tests, H0 : βk = 0 vs H1 : βk 6= 0. In order to
express the null and non-null biomarkers, we introduce the following latent structure
for the effect sizes:
G(βk) = pig0(βk) + (1− pi)g1(βk), (4)
6
where pi is the prior probability of being null, that is, pi = P (βk = 0), and the functions
g0 and g1 represent the distributions of the null and non-null biomarkers, respectively.
For null biomarkers, we use the one-point distribution on 0, that is, g0(·) = δ0(·),
where δc(x) represent the one-point distribution on x = c. The form of g1 is not
specified, so that the latent structure of βk can be seen as a semiparametric model
where a nonparametric distribution is assumed for non-null biomarkers. Combined
with the profile likelihood PLk and the prior (4), we define the following synthetic
posterior distribution of βk:
G(βk|Data) = PLk(βk)G(βk;pi, g1)∫
PLk(βk)G(βk;pi, g1)dβk
=
piPLk(βk)g0(βk) + (1− pi)PLk(βk)g1(βk)
piPLk(0) + (1− pi)
∫
PLk(βk)g1(βk)dβk
,
(5)
which are independent for k = 1, . . . , p.
The synthetic posterior distribution (5) have hyperparameters pi and g1. We
consider an empirical Bayes approach, that is, we estimate these parameters from the
synthetic marginal likelihood:
p∏
k=1
∫
PLk(βk)G(βk;pi, g1)dβk
=
p∏
k=1
{
piPLk(0) + (1− pi)
∫
PLk(βk)g1(βk)dβk
}
.
(6)
We employ the smoothing-by-roughening approach (Shen and Louis, 1999) in which
the nonparametric estimate of g1 is supported by fixed discrete mass points, that
is, we approximate g1(x) as
∑L
`=1 p`δa`(x) with mixing probabilities p`’s such that∑L
`=1 p` = 1, and fixed knots a1, . . . , aL. Then, the above synthetic likelihood can be
efficiently maximized by an EM algorithm (Dempster et al., 1977) whose details are
provided in Appendix.
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2.3 Biomarker-specific indices
Some biomarker-specific indices are useful for screening biomarkers. Let γk be the
indicator variable for null/non-null status for the kth biomarkers, such that γk = 1
if the kth biomarker is non-null and γk = 0 otherwise. The value of γk is unknown
and has the prior probability P (γk = 1) = 1 − pi. From the synthetic posterior (5),
we can compute the posterior probability of being non-null as
P (γk = 1|Data) = (1− pi)
∫
PLk(βk)g1(βk)dβk
piPLk(0) + (1− pi)
∫
PLk(βk)g1(βk)dβk
,
where the integral can be expressed as summation over the discrete mass points
used to estimate g1. By plugging in the hyperparameter estimates of pi and g1, the
estimated posterior probability of being non-null can be obtained. Other biomarker-
specific indices (e.g. posterior mean of βk) can also be estimated based on the syn-
thetic posterior distribution (5).
2.4 Screening biomarkers based on the optimal discovering procedure
For ranking biomarkers, we apply the optimal discovery procedure (Storey, 2007;
Storey et al., 2007), and use the following statistic:
ODSk =
∫
PLk(βk)ĝ1(βk)dβk
PLk(0)
,
which is the model-based version of the optimal discovery statistic (Cao et al., 2009;
Noma and Matsui, 2012, 2013). Since the optimal discovery procedure is known to
provide maximum expected number of significant biomarkers under given a certain
false discovery rate (Noma and Matsui, 2012), we may efficiently detect predictive
biomarkers by using the statistic ODSk. We select a set of Θ(λ) of biomarkers whose
ODS values are equal to or greater than λ. To estimate the number of false positives
in the selected set, we oblate a false discovery rate (FDR) based on the fitted model
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(e.g. McLachlan et al., 2006).
FDR(λ) =
1
|Θ(λ)|
∑
k∈Θ(λ)
P̂ (γk = 0|Data),
where |Θ(λ)| represents the size of Θ(λ), the number of selected biomarkers. Note
that the summation of P̂ (γk = 0|Data) (posterior probability of being null) represents
the expected number of null (false-positive) biomarkers in Θ(λ). For specified value
of λ, we may compute FDR, so that we may compute the reasonable value of λ under
user-specified FDR (e.g. 5%).
3 Simulation study
We here assessed the performance the proposed methods together with some alter-
native methods. We considered two types of responses: binary and censored survival
responses. We set n = 1000 (the number of samples) and p = 3000 (the num-
ber of candidate biomarkers) throughout this study. We generated the covariates
(X1, . . . , Xp) from a mean zero multivariate normal distribution with covariance ma-
trix whose (i, j)-element is (0.1)|i−j|. The treatment indicator T was indecently gen-
erated from a Bernoulli distribution with probability logistic(0.2X1 + 0.1X2), where
logistic(x) = exp(x)/(1 + exp(x)).
We first consider the case with binary response. We generated n independent
samples from the following model:
Y = I
(
p∑
k=1
γkXk +
p∑
k=1
δkX
2
k + T
p∑
k=1
βkXk + ε > 0
)
,
where ε ∼ N(0, 52). For the true parameter values of the main effect, we set γ1 =
γ3 = γ5 = 0.2, γ2 = γ4 = γ6 = −0.2, δ1 = δ3 = δ5 = 0.2, δ2 = δ4 = δ6 = −0.2, and
the other values of γk’s and δk’s were set to 0. For effect sizes βk in the interaction
term, we consider the following generating distribution
f(x) = piδ0(x) + (1− pi)0.3φ(x; 0.2, (0.1)2 + (1− pi)0.7φ(x;−0.5, (0.1)2),
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so that the distribution of βk consists of three components, one-point distribution on
0 representing null effect, two normal distributions with positive and negative means
representing biomarkers that have positive and negative values on the individual
treatment effects, respectively. We considered two cases of null probability pi of
0.5 and 0.7. For the simulated dataset, we applied the proposed ODP methods
with the use of negative log-binomial likelihood function for the loss function. As
explained in Section 2, we considered two approaches for constructing the synthetic
profile likelihood: the plug-in method and the normal-approximation method, which
are denoted by ODP-P and ODP-N, respectively. For estimating unknown non-
null distribution, we adopted knots (−1.00,−0.98, . . . ,−0.02, 0.02, . . . , 0.98, 1.00). As
conventional screening methods, we used the standardized test statistics for the kth
biomarkers:
Tk =
β̂k
sk
, Sk =
β̂k1 − β̂k0√
s2k1 + s
2
k0
, (7)
where β̂kj and skj are estimate and standard error based on the single logistic regres-
sion on kth biomarker in treatment (j = 1) and control (j = 0) groups. The FDR for
these tests were estimated using the method by Storey and Tibshirani (2003).
We next consider the case with survival responses. We generated n independent
survival times from the following regression model:
Y˜ = exp
(
p∑
k=1
γkXk +
p∑
k=1
δkX
2
k + T
p∑
k=1
βkXk + ε
)
,
where ε ∼ N(0, 52) and all the model parameters were the same as those in the
previous parts. The censoring time was generated from the uniform distribution
U(20, 60), which induced censoring survival time Y . The censoring rate was around
30% in each simulated dataset. For the simulated dataset, we applied the proposed
two ODP methods (ODP-P and ODP-N) with the use of negative log Cox partial
likelihood function for the loss function. As competitors, we adopted the same form
of test statistics as (7), where β̂kj and skj are obtained from Cox regression with only
kth biomarker in treatment (j = 1) and control (j = 0) groups.
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Based on 200 simulations, we calculated the average number of significant biomark-
ers and true positives at FDR=5, 10, 15, or 20% for three types of responses, which
are summarized in Table 1. Overall, the proposed methods detected the large num-
bers of biomarkers than the standard methods, which clearly shows the efficiency
of the propose methods. Moreover, the numbers of true positives of the proposed
methods are much larger than the standard methods when we allow larger FDR.
Also the efficiency gain of the proposed method emerged as pi (null probability) gets
smaller. Comparing the two proposed methods, ODP-P tends slightly more efficient
than ODP-N possibly because the approximation error of the normal approximation
used in ODP-N may not be negligible and it may reduce the power of ODP-N.
Table 1: Average numbers of significant biomarkers and true positives for the pro-
posed and alternative methods based on 200 simulations.
# significant biomarkers # true positive
FDR levels 5% 10% 15% 20% 5% 10% 15% 20%
Binary (pi = 0.8)
ODP-P 1.29 5.74 13.38 24.49 1.14 4.70 10.44 17.86
ODP-N 0.85 4.21 10.74 20.68 0.76 3.56 8.47 15.45
Tk 0.52 1.41 2.97 5.04 0.47 1.13 2.32 3.90
Sk 0.68 1.63 3.42 5.65 0.60 1.34 2.71 4.33
Binary (pi = 0.5)
ODP-P 1.00 6.51 18.45 38.67 0.90 5.54 15.04 30.66
ODP-N 0.62 4.84 15.05 33.38 0.58 4.18 12.32 26.63
Tk 0.37 1.05 2.15 3.71 0.33 0.93 1.86 3.12
Sk 0.52 1.10 2.33 4.11 0.45 0.99 1.97 3.37
Survival (pi = 0.8)
ODP-P 3.89 13.37 26.74 44.13 3.45 11.20 21.15 33.12
ODP-N 3.46 12.19 24.77 41.37 3.15 10.24 19.59 31.23
Tk 1.51 3.79 7.38 12.67 1.34 3.28 5.99 9.80
Sk 1.35 3.32 6.49 11.69 1.23 2.88 5.35 9.11
Survival (pi = 0.5)
ODP-P 1.49 10.48 29.73 61.36 1.33 9.06 24.84 49.46
ODP-N 1.07 8.78 25.96 54.67 0.96 7.61 21.71 44.25
Tk 0.52 1.40 3.02 5.74 0.46 1.24 2.58 4.70
Sk 0.48 1.07 2.61 5.00 0.42 0.94 2.17 4.13
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4 Application to a breast cancer clinical study
In this section, we illustrate the practical application of the proposed method in a
breast cancer clinical study (Loi et al., 2007). The dataset consisted of 414 estro-
gen receptor (ER)-positive breast cancer patients with microarray gene expression
profiling data. We applied the proposed ODP method to detect the significant gene
expression associated with the individual treatment effects. The data are available
from the NCBI GEO database (GSE 6532). Here we adopted the time to relapse-free
survival (RFS) as the outcome. After excluding patients with incomplete informa-
tion, there were 268 and 125 patients receiving tamoxifen and alternative treatments,
respectively. For each patient, 44928 gene expression measurements were available.
For estimating the propensity score pi(X), we employed the following logistic linear
regression:
P (T = 1|X) = logistic
(
γ0 +
p∑
k=1
γkXk
)
.
We estimated the regression coefficients penalized likelihood with lasso (Tibshirani,
1996), where the tuning parameter was selected by 10-fold cross validation. With
use of the estimated propensity score, we applied the two types of proposed ODP
methods, ODP-P and ODP-N, with negative log-binomial likelihood. The estimated
null probabilities were 0.82 and 0.74 for ODP-N and ODP-P, respectively, and esti-
mated underlying distributions of effect sizes are shown in the right panel of Figure 1
with histogram of t-values of each biomarker. From Figure 1, both methods produced
similar estimates of the underlying distribution, and the true underlying distribution
of effect sizes would not have a simple form and seem right skewed. The numbers of
detected microarrays with different FDR values based on the propose methods and
the two standard methods describe in Section 3 are reported in Table 2. The proposed
methods were able to detected much larger numbers of microarrays than the direct
use of q-values with statistics Tk and Sk. Also, ODP-P found more microarrays than
ODP-N possibly because the normal approximation is not accurate in this situation
where n is around 400.
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Figure 1: Histogram of t-values of genes (left) and estimated distribution of underlying
effect sizes (right) in breast cancer data.
Table 2: The numbers of detected genes in breast cancer data.
FDR levels 5% 10% 15% 20%
ODP-P 23 65 125 218
ODP-N 10 26 47 75
Tk 1 2 2 2
Sk 0 0 0 0
5 Discussions
We developed an efficient method for detecting predictive biomarkers associated with
individual treatment effects based on the optimal discovery procedure with the syn-
thetic posterior for effect sizes. The key feature of our approach is to employ the
idea of direct estimation of individual treatment effect via the weighted loss function
(Chen et al., 2017) and combine the semi-parametric prior for interaction effects,
which enables flexible and efficient estimation of the underlying signal components.
Employing the empirical Bayes method, the signal components can be accurately
estimated from the data. Then, the estimated model is combined with the optimal
discovery procedure to make up a effective screening procedure under which the treat-
ment effects are heterogenous, i.e. there exist predictive biomarkers. The advantage
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of the proposed method compared with existing approaches was confirmed through
simulation study and the application to breast cancer data.
Although we employed the weighted loss function Chen et al. (2017) for construct-
ing synthetic posterior distribution (5), other types of loss functions can be readily
used in the proposed method by simply changing the formula of synthetic likelihood
(2). For instance, A-learning method (Murphy, 2003; Lu et al., 2013; Ciarleglio et al.,
2015), which also can directly estimate individual treatment effect, would be useful
alternatives. Since the detailed investigation and comparison among several types of
loss functions would extend the scope of this paper, it is left to a future study.
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Appendix (EM algorithm)
Let φ = (pi, p1, . . . , pL) be the vector of unknown hyperparameters. We introduce
two types of latent variables, zk and wk (k = 1, . . . , p), such that P (zk = 1) =
1− P (zk = 0) = pi and P (wk = `) = p`. Then, logarithm of the synthetic likelihood
(6) can be augmented as
p∑
k=1
[
zk
{
PLk(0) + log pi
}
+ (1− zk)
L∑
`=1
I(wk = `)
{
PLk(a`) + log p`
}]
.
With current parameter values p
(t)
` and pi
(t), we have the following objective function
in the M-step:
Q(φ|φ(t)) =
p∑
k=1
[
ξ
(t)
k log pi + (1− ξ(t)k )
L∑
`=1
η
(t)
k` log p`
]
,
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where
ξ
(t)
k =
pi(t)PLk(0)
pi(t)PLk(0) + (1− pi(t))
∑L
`=1 p
(t)
` PLk(a`)
and η
(t)
k` =
p
(t)
` PLk(a`)∑L
j=1 p
(t)
j PLk(aj)
.
The updating steps are given by
pi(t+1) =
1
p
p∑
k=1
ξ
(t)
k and p
(t+1)
` =
1
p
p∑
k=1
η
(t)
k` , ` = 1, . . . , L.
Hence, each iteration in the EM algorithm requires computing ξ
(t)
k and η
(t)
k` as the
E-step and updating pi and p`’s as the M-step, which is continued until numerical
convergence.
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